BioHarvest Sciences Appoints Anna Tenstam as VP of Business Development, Cosmeceuticals and Injectables
BioHarvest Sciences Appoints Anna Tenstam as VP of Business Development, Cosmeceuticals and Injectables
Experienced Life Sciences Executive to Support Cosmeceuticals and Injectables Growth for New CDMO Business Unit
经验丰富的生命科学高管将支持新的CDMO业务部门的药妆品和注射剂的增长
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 21, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced the appointment of experienced life sciences executive Anna Tenstam as VP of Business Development, Cosmeceuticals and Injectables, to drive broader expansion of the Company's recently launched Contract Development and Manufacturing Organization ("CDMO") Services Business Unit.
不列颠哥伦比亚省温哥华和以色列雷霍沃特--(Newsfile Corp.,2024年3月21日)——开创其专利植物合成技术平台的生物技术公司BioHarvest Sciences Inc.(CSE:BHSC)(OTCQB:CNVCF)(“BioHarvest” 或 “公司”)今天宣布任命经验丰富的生命科学高管安娜·滕斯塔姆为药妆品和注射剂业务开发副总裁推动公司最近成立的合同开发和制造组织(“CDMO”)服务业务部门的更广泛扩张。
"Anna's business development acumen - paired with her extensive experience in life sciences - presents an incredible opportunity to accelerate our business with pharmaceutical, cosmeceutical, nutraceutical and nutrition industry leaders," said Ilan Sobel, Chief Executive Officer of BioHarvest Sciences. "Her invaluable relationships with global industry partners within these industries positions BioHarvest to attract development and long-term manufacturing contracts for our CDMO business unit. We look forward to working closely with Anna going forward as we continue to successfully scale operations, all with the goal of creating sustainable value for my fellow shareholder partners over the long-term."
BioHarvest Sciences首席执行官伊兰·索贝尔表示:“安娜的业务发展敏锐度,加上她在生命科学领域的丰富经验,为加快与制药、药品、营养品和营养行业领导者的业务发展提供了难得的机会。”“她与这些行业的全球行业合作伙伴的宝贵关系使BioHarvest能够为我们的CDMO业务部门吸引开发和长期制造合同。在我们继续成功扩大运营规模的过程中,我们期待与Anna密切合作,所有目标都是为我的股东合作伙伴创造长期可持续的价值。”
Anna Tenstam
安娜·滕斯塔姆
Anna Tenstam has over 30 years of leadership experience with pharmaceutical, medical devices and medical aesthetics companies worldwide, holding executive positions in several global companies in these industries. She has managed global brands and been involved in several license and exit deals with companies such as Colbar Lifescience/J&J, and Q-MED/Medicis/Galderma, among others. She currently serves on the Board of Daya Ventures, Oxagon AB, Medicortex Finland Oy and Optomed Plc, Finland. She holds an MSc from Uppsala University and an MBA from IMD Lausanne.
Anna Tenstam 在全球制药、医疗器械和医学美容公司拥有超过 30 年的领导经验,曾在这些行业的多家跨国公司担任高管职务。她曾管理过全球品牌,并参与了与Colbar Lifescience/J&J和Q-med/Medicis/Galderma等公司的多项许可和退出协议。她目前在Daya Ventures、Oxagon AB、芬兰Medicortex Oy和芬兰Optomed Plc的董事会任职。她拥有乌普萨拉大学的硕士学位和洛桑IMD的工商管理硕士学位。
Tenstam commented: "I am truly privileged to join the team at BioHarvest, and excited to focus on building partnerships with industry leaders who are searching for the next generation of therapeutic molecules. My chief focus at BioHarvest will be to uncover new opportunities within cosmeceuticals and injectables, with the goal of building revenues for the CDMO services business unit."
Tenstam评论说:“我很荣幸能加入BioHarvest的团队,也很高兴能专注于与正在寻找下一代治疗分子的行业领导者建立合作伙伴关系。我在BioHarvest的主要重点将是发现药妆和注射剂领域的新机会,目标是为CDMO服务业务部门创造收入。”
About BioHarvest Sciences Inc.
BioHarvest 科学公司简介
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit .
BioHarvest Sciences Inc.(CSE:BHSC)(场外交易代码:CNVCF)(FSE:8MV)是植物合成领域的领导者,利用其专利技术平台培育植物基分子,无需种植底层植物。BioHarvest正在利用其植物合成技术在两个主要垂直业务领域开发基于科学且经过临床验证的下一代治疗解决方案;作为代表寻求复杂分子的客户的合同开发和生产组织(CDMO),以及作为专有营养保健品健康和保健产品(包括膳食补充剂)的创造者。要了解更多信息,请访问。
Forward-Looking Statements
前瞻性陈述
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements.. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
本新闻稿中提供的信息可能包括基于管理层当前估计、信念、意图和预期的前瞻性陈述,并且存在许多风险和不确定性,这些风险和不确定性可能导致实际业绩与前瞻性陈述中描述的结果存在重大差异。所有前瞻性陈述本质上都是不确定的,实际结果可能会受到我们无法控制的许多重大因素的影响。读者不应过分依赖前瞻性陈述。除了通过我们的定期管理层讨论和分析披露外,BHSC无意更新前瞻性陈述披露。
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
加拿大证券交易所及其监管服务提供商均不对本新闻稿的充分性或准确性承担责任。
This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibility for its contents.
本新闻稿已由投资者关系副总裁戴夫·瑞安审查和批准,他对其内容承担责任。
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
+1 (604) 622-1186
info@bioharvest.com
BioHarvest 公司联系方式
投资者关系副总裁兼董事戴夫·瑞安
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us
投资者关系联系人:
卢卡斯·A·齐默尔曼
董事总经理
MZ 集团-MZ 北美
+1 (949) 259-4987
BHSC@mzgroup.us